N Biglia1, L Sgro, E Defabiani, G De Rosa, R Ponzone, D Marenco, P Sismondi. 1. Gynaecological Oncology Unit, Institute for Cancer Research and Treatment (IRCC) of Candiolo and Mauriziano Umberto I Hospital, University of Turin, Largo Turati 62, 10128 Turin, Italy.
Abstract
AIM OF THE STUDY: To assess whether the pathological characteristics of breast carcinomas arising in post-menopausal women who ever used hormonal replacement therapy (HRT) differ from those of post-menopausal patients who never used HRT. MATERIALS AND METHODS: Six hundred and forty three consecutive breast cancer patients were entered in a case control-study. Cases were represented by 111 breast cancer patients who had used or were using HRT at the time of diagnosis, while the remaining 532 patients who never used HRT were chosen as controls. RESULTS: Tumour diameter was smaller in HRT users (17.6 vs 22.1 mm; p=0.002) and tumours of lobular histology were almost twice more frequent among HRT users as in 'never users' (21 vs 12%; p=0.01). No differences were found in grading, hormonal receptor status and axillary nodal status. The expression of c-erb B-2, p53, Ki67 and PS2 measured by immunohistochemistry was similar in the two groups. CONCLUSIONS: Our findings suggest that HRT use may modify the pathological presentation of breast cancer. Further studies are indicated, while other clinical-pathological characteristics did not differ according to HRT use.
AIM OF THE STUDY: To assess whether the pathological characteristics of breast carcinomas arising in post-menopausal women who ever used hormonal replacement therapy (HRT) differ from those of post-menopausal patients who never used HRT. MATERIALS AND METHODS: Six hundred and forty three consecutive breast cancerpatients were entered in a case control-study. Cases were represented by 111 breast cancerpatients who had used or were using HRT at the time of diagnosis, while the remaining 532 patients who never used HRT were chosen as controls. RESULTS: Tumour diameter was smaller in HRT users (17.6 vs 22.1 mm; p=0.002) and tumours of lobular histology were almost twice more frequent among HRT users as in 'never users' (21 vs 12%; p=0.01). No differences were found in grading, hormonal receptor status and axillary nodal status. The expression of c-erb B-2, p53, Ki67 and PS2 measured by immunohistochemistry was similar in the two groups. CONCLUSIONS: Our findings suggest that HRT use may modify the pathological presentation of breast cancer. Further studies are indicated, while other clinical-pathological characteristics did not differ according to HRT use.
Authors: Kerryn W Reding; David R Doody; Anne McTiernan; Li Hsu; Scott Davis; Janet R Daling; Peggy L Porter; Kathleen E Malone Journal: Breast Cancer Res Treat Date: 2010-09-29 Impact factor: 4.872
Authors: Kerryn W Reding; Chu Chen; Kimberly Lowe; David R Doody; Christopher S Carlson; Christina T Chen; John Houck; Linda K Weiss; Polly A Marchbanks; Leslie Bernstein; Robert Spirtas; Jill A McDonald; Brian L Strom; Ronald T Burkman; Michael S Simon; Jonathan M Liff; Janet R Daling; Kathleen E Malone Journal: Cancer Causes Control Date: 2012-03-15 Impact factor: 2.506
Authors: Rainer Fagerholm; Maria Faltinova; Kirsi Aaltonen; Kristiina Aittomäki; Päivi Heikkilä; Mervi Halttunen-Nieminen; Heli Nevanlinna; Carl Blomqvist Journal: Fam Cancer Date: 2018-07 Impact factor: 2.375